GHRP-6 5mg Dosage Protocol | PeptideDosages.com

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

GHRP-6 (5 mg Vial) Dosage Protocol

GHRP-6 Dosage Chart

GHRP-6 is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.

Typical daily range: 300–900 mcg total (split into 3 doses with gradual titration).

Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days.

GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a)[1][2]. It stimulates pulsatile GH release from the pituitary gland while maintaining physiological feedback controls, resulting in elevated IGF-1 levels and potential anabolic benefits[3]. This educational protocol presents a three-times-daily subcutaneous approach using practical dilution for precise insulin-syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read GHRP-6 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Weeks 1–2

100 mcg

6 units (0.06 mL)

Weeks 3–4

200 mcg

12 units (0.12 mL)

Weeks 5–12

300 mcg

18 units (0.18 mL)

Frequency: Inject three times daily subcutaneously, spaced at least 4 hours apart (morning, midday, bedtime). GHRP-6 has a short half-life of approximately 2.5 hours[4], making multiple daily injections more effective than once-daily dosing for sustained GH elevation[5]. Each injection should be administered on an empty stomach (2–3 hours after meals, 30 minutes before eating) to maximize GH release[6].

For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall to avoid foaming; do not shake.

Gently swirl or roll the vial until the powder is completely dissolved.

Label with date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Use within 7 days of reconstitution for optimal potency.

Supplies Needed

Plan based on a 12-week protocol with three-times-daily injections and gradual titration.

Peptide Vials (GHRP-6, 5 mg each):

12 weeks ≈ 13 vials (based on gradual titration to 300 mcg × 3 daily)

Insulin Syringes (U-100):

Per week: 21 syringes (3/day × 7 days)

12 weeks: 252 syringes (recommend 3 × 100-count boxes)

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

12 weeks (13 vials): 39 mL → 4 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site per injection.

Per week: 42 swabs (2 per injection × 3 daily × 7 days)

12 weeks: 504 swabs → recommend 6 × 100-count boxes

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

02Teduglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Teduglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

03Amycretin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

04VK2735 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. VK2735 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

05Retinalamin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Retinalamin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

Research context

Read sources and limitations before applying a claim.

Limitations and the Human-Evidence Gap

Every honest account of NAD+ and Parkinson’s disease converges on the same conclusion: the human evidence gap is wide, and the most important results are not yet in. It is worth cataloguing the specific limitations, because they are what separate a promising research program from a proven therapy, and because they are exactly the details that hype tends to omit. The first limitation is trial size and duration. The two completed randomized trials in Parkinson’s disease enrolled 30 and 20 participants and lasted 30 days and 4 weeks respectively.1,2 These are appropriate designs for their stated purposes, safety and target engagement, but they are structurally incapable of demonstrating disease modification, which manifests as a gradual divergence of progression curves over a year or more. Any clinical improvement seen in such short trials is more likely to reflect symptomatic effects, measurement variability, or confounding than a change in the underlying neurodegenerative process. The NR-SAFE authors’ own caution about levodopa-timing confounding their UPDRS signal is a model of the appropriate humility.2 The second limitation is the responder problem. NADPARK showed that oral NR raises brain NAD+ in some participants but not others, and that clinical and metabolic signals clustered in the responder subgroup.1 This heterogeneity is scientifically important but clinically double-edged: it means that even if NAD+ elevation helps, an intention-to-treat analysis that includes non-responders may dilute the effect below detectability, while a responder-only analysis risks the statistical pitfalls of post-hoc subgrouping. Sorting out who responds, why, and how to identify them in advance is unfinished work. The third limitation is the model-to-human translation gap already discussed. The mechanistic and preclinical case is strong, but Parkinson’s disease has an unusually long history of interventions that protected neurons in animals and then failed in rigorous human trials, from antioxidants to anti-apoptotic agents to other mitochondrial strategies. NAD+ boosting could be different, but the base rate argues for caution until the phase III data are published.1,5 The fourth limitation concerns the epidemiology: the cross-sectional NHANES analysis linking higher dietary niacin intake to lower Parkinson’s prevalence is consistent with the hypothesis but cannot establish causation, and the larger EPIC-based cohort study examined niacin and tryptophan intake against incident Parkinson’s disease without providing the kind of confirmed protective association that would strengthen the causal case.10,11 Observational designs of this type are in any event particularly vulnerable to reverse causation, because prodromal Parkinson’s disease alters diet, smell, appetite, and gastrointestinal function years before diagnosis. The fifth limitation is conceptual: “NAD+ deficiency” is not a single, cleanly measured, universally agreed entity in Parkinson’s disease. Different studies measure NAD+ in different tissues (brain, cerebrospinal fluid, blood, skeletal muscle) using different techniques, and these compartments do not move in lockstep. The finding of lower NAD+ or lower NAD+-synthesizing enzymes in some Parkinson’s tissues is real and reproducible in places, but whether it is a primary driver of neurodegeneration, a downstream consequence of mitochondrial failure, or both at once is not resolved.4,6 A therapy premised on correcting a deficiency needs a clear picture of what deficiency it is correcting and where. Until the NOPARK results and comparable trials are published and, ideally, independently replicated, the responsible bottom line is that NAD+ precursors remain an unproven, investigational approach in Parkinson’s disease, however biologically attractive the rationale.3

Source: dosagepeptide.com ↗

Why Dermorphin draws research interest

These are the directions researchers and the peptide community most often explore Dermorphin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Source: dosagepeptide.com ↗

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Cerebrolysin Dosage Chart

Cerebrolysin is dosed at 20 mg–32 mg daily via subcutaneous injection in educational protocols. A 60 mg vial reconstituted with bacteriostatic water yields about 20 mg/mL. This information is for research and educational use only. Reconstitute: Add 3.0 mL bacteriostatic water → 20 mg/mL concentration. Typical daily range: 20–32 mg once daily (gradual titration); split doses for >20 mg. Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 200 mcg (0.2 mg) on a U‑100 insulin syringe. Storage: Lyophilized at room temperature ≤25 °C (≤77 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days; do not freeze. Cerebrolysin is a porcine brain‑derived peptide preparation containing low‑molecular‑weight neuropeptides and free amino acids that crosses the blood–brain barrier to support neuronal survival[1]. It mimics endogenous neurotrophic factors (e.g., NGF, BDNF) and modulates neuroinflammatory mediators[1][2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements. Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Cerebrolysin Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Source: peptidedosages.com ↗

Storage reference

Storage Instructions

Proper storage preserves compound stability. Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[4]. Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks. Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues. Do not refreeze reconstituted solution.

Source: peptidedosages.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

GHRP-6 (5 mg Vial) Dosage Protocol

GHRP-6 Dosage Chart

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Reconstitution Steps

Supplies Needed

Related questions

Limitations and the Human-Evidence Gap

Why Dermorphin draws research interest

Cerebrolysin Dosage Chart

Storage Instructions

Peptide Therapy Guide Editorial Team

Vilon Dosage Protocol | PeptideDosages.com

Vesugen Dosage Protocol | PeptideDosages.com

Testagen Dosage Protocol | PeptideDosages.com

SS-31 30mg Dosage Protocol | PeptideDosages.com